Page 46 - Demo
P. 46
62. Miao HZ, Sirachainan N, Palmer L, et al.Bioengineering of coagulation factor VIII forimproved secretion. Blood 2004; 103: 3412-9.https://doi.org/10.1182/blood-2003-10-3591.63. Follenzi A, Battaglia M, Lombardo A, et al.Targeting lentiviral vector expression tohepatocytes limits transgene- specificimmune response and establishes long-termexpression of human antihemophilic factorIX in mice. Blood 2004; 103: 3700-9.https://doi.org/10.1182/blood-2003-09-3217.64. Barcellona D, Marongiu F. The hemostaticsystem. 1st Part. J Pediatr Neonatal IndividMed 2020; 9: e090106.https://doi.org/10.7363/090106.44ANALESRANFwww.analesranf.comD%u00e9ficit de factor V y terapias avanzadasAntonio Liras et al.An. R. Acad. Farm.Vol. 91. n%u00ba1 (2025) %u00b7 pp. 17-44Si desea citar nuestro art%u00edculo:D%u00e9ficit de factor V y terapias avanzadasAntonio Liras, Sara Bernal, Luis J. Serrano, Pablo Bermejo-%u00c1lvarez,Andrea Miguel- Batuecas, Dami%u00e1n Garc%u00eda-Olmo, Mariano Garcia-Arranz, Mar%u00eda Garc%u00eda-Bravo, Jos%u00e9 Carlos Segovia,Leopoldo Gonz%u00e1lez-Brusi, Javier M. De Pablo-Moreno, Antonio Rodr%u00edguez- Bertos, A%u00edda Garc%u00eda-Torralba, M. Jos%u00e9 Extremera,M. Dolores Camero, Luis Revuelta, Juan A. de Pablo-Moreno.An Real Acad Farm (Internet).An. Real Acad. Farm.Vol. 91. n%u00ba 1 (2025) %u00b7 pp. 17-44DOI:http://dx.doi.org/10.53519/analesranf.2025.91.01.01
